OverviewChartProfileKey statisticsFinancialsNews
Derivatives
TraderScreen

VIATRIS INC. O.N./  US92556V1061  /

Xetra
2024-05-17  5:35:50 PM Chg. -0.150 Volume Bid2024-05-17 Ask5:41:48 PM Market Capitalization Dividend Y. P/E Ratio
10.130EUR -1.46% 805
Turnover: 8,221.435		 -Bid Size: - -Ask Size: - 12.03 bill.EUR - -
GlobeNewswire 05-10 Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
GlobeNewswire 05-06 Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting
GlobeNewswire 05-03 Ocuphire Pharma to Present at the Aegis Virtual Conference
GlobeNewswire 05-01 NeurologyLive® and CMSC Announce the 3rd Annual Class of Inductees
GlobeNewswire 04-22 Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
GlobeNewswire 04-11 First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS...
GlobeNewswire 04-01 Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) b...
GlobeNewswire 03-20 Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Boar...
GlobeNewswire 03-08 Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corpo...
TeleTrader 02-28 US closes lower after GDP data, ahead of earnings
GlobeNewswire 02-28 Idorsia and Viatris enter into a significant global research and development collaboration
GlobeNewswire 02-23 Ocuphire Pharma to Present in the BIO CEO & Investor Conference
GlobeNewswire 02-15 Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 02-14 ACTG Announces Launch of Clinical Trial Evaluating Drug-Drug Interaction in Shortened Tuberculosis R...
GlobeNewswire 02-14 Ocuphire Pharma Strengthens Leadership Team with Key Appointments
GlobeNewswire 02-05 Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degener...
GlobeNewswire 02-02 Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
GlobeNewswire 01-24 Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 01-04 Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of...
GlobeNewswire 01-02 VIATRIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Viatris Inc. on Behalf of Long-Term Stoc...
GlobeNewswire 2023-11-30 Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII
GlobeNewswire 2023-11-30 Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries ...
GlobeNewswire 2023-11-27 Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 2023-11-27 Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
GlobeNewswire 2023-11-13 Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update